Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

CureVac N.V. - Ordinary Shares (NQ: CVAC )

4.100 -0.080 (-1.91%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about CureVac N.V. - Ordinary Shares

< Previous 1 2 3 Next >
CureVac Announces Update to the Management Team
Via ACCESSWIRE
CureVac Strengthens Ongoing Patent Litigations Bringing Additional Cases Under New Intellectual Property Rights
Via ACCESSWIRE
CureVac Doses First Patient in Phase 1 Study of Cancer Vaccine Candidate for Surgically Resected Glioblastoma
Via ACCESSWIRE
CureVac Appoints International Financial Expert Michael Brosnan to Supervisory Board
Via ACCESSWIRE
CureVac Announces Voting Results of General Meeting
Via ACCESSWIRE
CureVac Announces Financial Results for the First Quarter of 2023 and Provides Business Update
Via ACCESSWIRE
CureVac Announces Developments in Patent Litigation with Pfizer/BioNTech
Via ACCESSWIRE
CureVac Announces Dosing of First Participant in Combined Phase 1/2 Study of Multivalent, Modified Influenza Vaccine Candidates Developed in Collaboration with GSK
Via ACCESSWIRE
CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2022 and Provides Business Update
Via ACCESSWIRE
CureVac to Report Fourth Quarter and Full-Year 2022 Financial Results and Business Updates on April 25, 2023
Via ACCESSWIRE
CureVac Announces Voting Results of Extraordinary General Meeting
Via ACCESSWIRE
CureVac Announces Closing of $250 million Follow-on Public Offering of Common Shares
Via ACCESSWIRE
CureVac Announces Proposed Public Offering of Common Shares
Via ACCESSWIRE
CureVac Welcomes Myriam Mendila as New Chief Development Officer
Via ACCESSWIRE
CureVac Named as One of the World’s Most Dynamic Innovators by LexisNexis(R)
Via ACCESSWIRE
CureVac Announces Positive Data in Older Adults from COVID-19 and Flu mRNA Vaccine Development Programs
Via ACCESSWIRE
CureVac Appoints Alexander Zehnder as CEO From April 1, 2023
Via ACCESSWIRE
CureVac Announces Positive Data on Joint COVID-19 and Flu mRNA Vaccine Development Programs
Via ACCESSWIRE
CureVac Members of Management Sell Shares to Cover Tax Obligations from Long Term Incentive Program
Via ACCESSWIRE
CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2022 and Provides Business Update
Via ACCESSWIRE
CureVac Presents Preliminary Data from Phase 1 Study Expansion of Oncology Candidate CV8102
Via ACCESSWIRE
CureVac to Report Third Quarter and First Nine Months 2022 Financial Results and Business Updates on November 16, 2022
Via ACCESSWIRE
CureVac Announces Financial Results for the Second Quarter and First Half of 2022 and Provides Business Update
Via ACCESSWIRE
CureVac Starts Phase 1 Clinical Study of Modified, Omicron-Targeting COVID-19 Vaccine Candidate
Via ACCESSWIRE
CureVac Files Patent Infringement Lawsuit in Germany Against BioNTech
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / July 5, 2022 / CureVac N.V. (NASDAQ:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger... 
From CureVac
Via AccessWire
Topics Intellectual Property Lawsuit
Exposures COVID-19 Financial Intellectual Property
CureVac Announces Voting Results of General Meeting
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / June 22, 2022 / CureVac N.V. (Nasdaq:CVAC), a global clinical-stage biopharmaceutical company developing a new class of transformative medicines based on... 
From CureVac
Via AccessWire
Exposures COVID-19
CureVac Accelerates Oncology Strategy with Acquisition of Frame Cancer Therapeutics, Adding Novel Antigen Discovery Platform
TÜBINGEN, GERMANY and AMSTERDAM, NETHERLANDS / ACCESSWIRE / June 8, 2022 / CureVac N.V. (NASDAQ:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on... 
From CureVac
Via AccessWire
CureVac Announces Changes of CDO - Myriam Mendila to Succeed Klaus Edvardsen
TÜBINGEN, DEUTSCHLAND and BOSTON, MA / ACCESSWIRE / June 8, 2022 / CureVac N.V. (NASDAQ:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger... 
From CureVac
Via AccessWire
CureVac Partners with myNEO to Identify Novel Antigen Targets for mRNA-Based Cancer Vaccine Development
TÜBINGEN, GERMANY and GHENT, BELGIUM / ACCESSWIRE / May 25, 2022 / CureVac N.V. (Nasdaq:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger... 
From CureVac
Via AccessWire
Curevac Announces Financial Results For The First Quarter Of 2022 And Provides Business Update
TÜBINGEN, GERMANY and BOSTON MA / ACCESSWIRE / May 25, 2022 / CureVac N.V. (Nasdaq:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger... 
From CureVac
Via AccessWire
Exposures COVID-19
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.